Evidence map›Paper›PMID 36751624›Full record

ArticleClinical kidney journal2023

Acute and chronic kidney disease and risk of hospital mortality during COVID-19 pandemic waves in the pre-vaccination era.

José Portolés, Paula López-Sánchez, Leyre Martin-Rodríguez, María Luisa Serrano-Salazar, Maria Valdenebro-Recio, Antonio Ramos, Rosa María Malo, Felipe Zalamea, Juan Manuel Martin-Giner, María Marques and 1 more

Open access · goldAbstract read
In one paragraph

Article in Clinical kidney journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

José PortolésNephrology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.ORCID https://orcid.org/0000-0002-2114-1385
Paula López-SánchezNephrology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.ORCID https://orcid.org/0000-0002-4332-5759
Leyre Martin-RodríguezNephrology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.ORCID https://orcid.org/0000-0001-5854-0577
María Luisa Serrano-SalazarNephrology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.ORCID https://orcid.org/0000-0002-6230-6377
Maria Valdenebro-RecioNephrology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Antonio RamosInfectious Disease Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Rosa María MaloPneumology and Lung Transplant Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Felipe ZalameaNephrology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Juan Manuel Martin-GinerInformation Technology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
María MarquesNephrology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.ORCID https://orcid.org/0000-0001-9691-2546
Alberto OrtizNephrology Department, Fundación Jiménez Díaz, Madrid, Spain.ORCID https://orcid.org/0000-0002-9805-9523
Hospital Universitario Puerta de Hierro Majadahonda · ESIntel (United States) · USSpanish Clinical Research Network · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic kidney disease (CKD) is a risk factor for death from coronavirus disease 2019 (COVID-19), and COVID-19 may cause acute kidney injury (AKI) which also influences outcomes. There is little information on the independent contribution of CKD and AKI to the risk of death in COVID-19 on different waves, as CKD is a key risk factor for AKI. Methods: We have studied the epidemiology of CKD and AKI in 2878 patients hospitalized for COVID-19 and their independent association with in-hospital mortality in the two largest pre-vaccination COVID-19 waves in Madrid, Spain. Hospitalized COVID-19 patients were grouped into four mutually exclusive categories: previous-CKD, community-acquired AKI (CA-AKI), hospital-acquired AKI (HA-AKI) and normal renal function throughout hospitalization. Results: Pre-existent or acquired kidney involvement was observed in 35.5% and 36.8% of COVID-19 patients in the 1st and 3rd waves, respectively. Overall, 13.9% of patients with normal kidney function on arrival developed HA-AKI. In the 3rd wave, CA-AKI was more common than in the 1st wave. Overall, 9%-20% of CKD cases and 22%-40% of AKI cases remained undiagnosed in the discharge report. CKD, CA-AKI and HA-AKI were independently associated with risk of death in multivariate analysis, with HA-AKI, which was usually mild, being the most relevant independent risk factor for in-hospital mortality. A model including kidney involvement category, age, Charlson index, admission lactate dehydrogenase and lymphocytes predicted death with a receiver operating characteristic area under the curve of 0.898. Conclusion: In conclusion, CKD and AKI were common in pre-vaccination waves among hospitalized COVID-19 patients and were independent risk factors for death, even when AKI was mild to moderate, and despite improvements in treatment.

Indexed as

acute kidney injurychronic kidney diseaseCOVID-19epidemiologymortalitySARS-CoV-2

Identifiers

PMID36751624
PMCPMC9620382
OpenAlexW4307515150

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.